CoLucid Pharmaceuticals, Inc. 4
4 · CoLucid Pharmaceuticals, Inc. · Filed Mar 1, 2017
Insider Transaction Report
Form 4
Skwierczynski Raymond
Head,Pharmaceutical Operations
Transactions
- Disposition to Issuer
Employee Stock Option (Right to Buy)
2017-03-01$40.81/sh−90,000$3,672,900→ 0 totalExercise: $5.69Exp: 2025-11-30→ Common Stock (90,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2017-03-01$39.75/sh−15,000$596,250→ 0 totalExercise: $6.75Exp: 2026-03-04→ Common Stock (15,000 underlying) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−3,615$168,098→ 0 total
Footnotes (4)
- [F1]Includes 3,568 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through February 19, 2017.
- [F2]Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
- [F3]These options, which provided that 25% of the shares vested on November 30, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
- [F4]These options, which provided for vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.